Search Results for peter mccullough

Higher myocarditis risk after COVID-19 than mRNA vaccination; contrary to Peter McCullough’s claim, young persons decrease their risk by getting vaccinated

Myocarditis, an inflammation in the heart muscle, is typically caused by viral infections. In rare instances, myocarditis can also occur after COVID-19 vaccination. During the global COVID-19 vaccination campaign, the mRNA vaccines have been linked to rare cases of post-vaccine myocarditis that are usually mild and resolve; these have occurred primarily in young males. On the other hand, COVID-19 itself carries a much higher risk of heart complications, including myocarditis. Moreover, the COVID-19 vaccines decrease the risk of COVID-19-related myocarditis, meaning that COVID-19 vaccination continues to be recommended to young persons.

Contrary to Peter McCullough’s claim, getting vaccinated is safer than getting COVID-19, in spite of rare cases of myocarditis

Although cases of myocarditis have been reported following mRNA vaccination against COVID-19, the cases are rare, usually mild and patients rapidly recover. In contrast, COVID-19 is associated with a higher rate of myocarditis with potential risks of clinical complications. Overall, based on all scientific evidence available, the benefits of vaccines largely outweigh their risks.

Joe Rogan interview with Peter McCullough contains multiple false and unsubstantiated claims about the COVID-19 pandemic and vaccines

To date, more than 241 million people in the U.S. have received at least one dose of COVID-19 vaccine. Clinical trials as well as the safety monitoring of COVID-19 vaccination campaigns provide overwhelming evidence that the vaccines’ benefits far outweigh their risks. There’s no evidence indicating that the amount of spike protein generated by mRNA vaccination is dangerous. The use of multiple doses of COVID-19 vaccines isn’t unusual or unprecedented; some childhood vaccines that have been used for decades also require four or more doses for complete immunization.

Vaccines are a safer alternative for acquiring immunity compared to natural infection and COVID-19 survivors benefit from getting vaccinated, contrary to claims by Peter McCullough

Clinical trials showed that COVID-19 vaccines are effective against the disease and have an excellent safety profile. While infection can also confer protective immunity, this also comes with the risks associated with disease, such as death and health complications. Vaccination develops immunity without running these risks, making vaccines the safer choice. COVID-19 survivors also benefit from vaccination. For example, vaccination may help prevent reinfection in survivors who don’t develop protective immunity from infection alone, while vaccine boosters can help build immunity to virus variants.

COVID-19 mRNA vaccines were tested in clinical trials, aren’t experimental

Clinical trials and ongoing vaccine monitoring efforts show that COVID-19 vaccines are effective at reducing a person’s risk of severe disease and death. Like any medical intervention, vaccines also come with risks. While COVID-19 mRNA vaccines are linked to a slight increase in the risk of myocarditis (inflammation of the heart muscle), COVID-19 itself is associated with a greater risk of heart inflammation and other health complications. On balance, the benefits of the COVID-19 mRNA vaccines outweigh their risks.

Modified RNA in COVID-19 vaccines isn’t linked to cancer development

The mRNA COVID-19 vaccines contain RNAs with chemical modifications that increase their stability and improve their ability to induce a potent immune response. Some results suggest that such chemical modifications make mRNA-based anti-cancer vaccines less effective. However, it doesn’t mean that COVID-19 vaccines increase the risk of cancer. There’s no evidence that COVID-19 vaccination increases the risk of cancer.

CDC analysis of RSV vaccines data showed vaccines are safe, not associated with excess deaths, contrary to claim by Children’s Health Defense

Respiratory Syncytial Virus (RSV) infections are very common during winter. Most of them are mild but complications can lead to pneumonia and bronchiolitis, especially in babies and older adults. RSV vaccines are effective and recommended for people above 60. Current evidence indicates their benefits outweigh their risks. Further research is needed to determine if these vaccines are associated with a higher risk of Guillain-Barré syndrome.